ERBB2 and breast carcinoma: SCHOLAR-2 is a multicenter, randomized trial that evaluates the safety and efficacy of continuing trastuzumab/pertuzumab/T-DM1 in patients with stage I-III HER2-positive breast cancer who develop systolic LV dysfunction defined as an LVEF < 54% or LVEF ≥ 54% and either a fall in LVEF of ≥15% from prior baseline or New York Heart Association class II heart failure symptoms within the past 6 months (NCT04680442) [48].